

Special Issue

Advances in Precision Medicine of Oncology Radiotherapy

Message from the Guest Editors

Radiation is one of the most effective therapies to cure cancer. A number of studies are ongoing, investigating new radiation techniques and alternative schedules for delivering doses, with the aim of improving the therapeutic window. omics approaches have great potential in radiation research. They can provide new ways to diagnose and study disease progression or relapse. This Special Issue will provide a comprehensive overview of the effects of radiotherapy combined with new systemic treatments, including target agents and immunotherapy. In addition, it will examine the feasibility of using modified dose fractionation schemes to kill cancer cells and boost the immune system. Possible topics for discussion in this Special Issue include predictive biomarkers, quality of life during cancer treatment, technical advances in radiotherapy, and new diagnostic methodologies that could be used to personalise therapies and predict outcomes.

Guest Editors

Dr. Giuseppe Iatì

Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy

Dr. Silvana Parisi

Radiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, 98122 Messina, Italy

Deadline for manuscript submissions

25 February 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/238469

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).